Following Malta's accession to the European Patent Convention early last month, the Federation received several requests for the clarification of Malta's patent situation with regard to the operations of the generic pharmaceutical manufacturing firms based in Malta.

To this end, the FOI organised a well-attended briefing for its members operating in this sector who were addressed by senior officials from Malta Enterprise. During the discussions, reference was also made to the Bolar provisions and any forthcoming changes to Maltese legislation that would affect manufacturers of generic medicines in Malta.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.